

- Diabetic ketoacidosis (DKA) (*Cont.*):  
prevention of, 2420  
treatment of, 64e-1-2, 318, 2419-2420, 2419t
- Diabetic nephropathy, **2424**  
clinical features of, 1835t  
epidemiology of, 1844  
glycemic control and, 2423  
microalbuminuria in, 1844, 2425, 2425f  
natural history of, 1844, 2425, 2425f  
pathogenesis of, 1813, 1832, 1844, 2424-2425  
renal biopsy in, 62e-8f, 1844  
treatment of, 1845, 2425-2426  
in type 1 vs. type 2 diabetes mellitus, 1844-1845, 2425
- Diabetic neuropathy, **2426**  
autonomic, 2426, 2427, 2642, 2682  
constipation in, 274  
distal symmetric sensory and sensorimotor polyneuropathy, 2682  
mononeuropathy, 2426, 2683  
pathophysiology of, 89  
polyneuropathy, 2426, 2683  
polyradiculopathy, 2426  
prevalence of, 2426  
proximal, 462e-19  
radiculoplexus neuropathy, 2682-2683  
risk factors for, 2426  
screening for, 2407  
treatment of, 93, 93t, 2426-2427, 2682t
- Diabetic retinopathy  
advanced, 206  
clinical features of, 40e-2f, 40e-4f, 2424, 2424f  
glycemic control and, 2423, 2423f  
treatment of, 206, 2424
- "Diabetic skin spots," 2429
- Diacetyl exposure, 1692
- Diagnostic hypothesis, 19-20
- Diagnostic imperative, 19-20
- Diagnostic tests. *See* Clinical laboratory tests
- Dialectical behavior therapy (DBT), 2720
- Dialysate, 1822
- Dialysis. *See* Hemodialysis; Peritoneal dialysis
- Dialysis access, 1823
- Dialyzer, 1822, 1824
- Diamines, 205e-7
- 3,4-Diaminopyridine, 2672, 2703
- Diamond-Blackfan anemia, 668, 669t
- Diapedesis, 416, 417f
- Diaper rash, 1343
- Diaphyseal aclasia (multiple exostoses), 426e-7
- Diarrhea  
acute, **265**. *See also* Diarrhea, infectious  
approach to the patient, 267, 267f  
etiology of, 265-267  
treatment of, 267-268  
after cholecystectomy, 2083  
antibiotic-associated, 267, 991, 1936. *See also* *Clostridium difficile*-associated disease  
in bacterial overgrowth syndrome, 1945  
bile acid, 1934-1935, 1935t  
bloody, 266, 266t, 267  
Brainerd, 267  
in carcinoid syndrome, 564  
in celiac disease, 1942  
chemotherapy-related, 103e-25, 103e-26  
chronic, **268**  
approach to the patient, 270-272, 271f, 271t  
definition of, 265  
endoscopic findings in, 1899, 1899f  
etiology of, 268-270, 268t  
in returning war veterans, 152e-8  
treatment of, 272  
in Crohn's disease, 1953  
definition of, 265  
diabetic, 270, 272, 855t, 1942  
differential diagnosis of, 1877, 1877t, 1932-1933  
with enteral feeding, 98e-9  
epidemiology of, 264  
fatty acid, 1935, 1935t  
in HIV infection, 1257, 1257f  
hypernatremia in, 303  
hypokalemia in, 305  
hyponatremia in, 298  
hypovolemia in, 298  
infectious, 266, **852**. *See also* Gastroenteritis;  
Travelers' diarrhea  
adenovirus, 266, 1208  
approach to the patient, 853-854, 854f  
*B. fragilis*, 1099  
bacterial vs. viral, 1287t. *See also* Gastroenteritis  
*Campylobacter*. *See* *Campylobacter* spp.  
infections  
clinical features of, 266, 266t, 1287t  
complications of, 854, 855t  
diagnosis of, 1031  
*E. coli*. *See* *Escherichia coli* infections,  
intestinal  
epidemiology of, 266, 855-856  
food-related, 266, 855-856, 856t. *See also* Food-related illness  
*Giardia*, 1406  
host defenses against, 853  
in immunodeficient persons, 266  
inflammatory, 852t  
in institutionalized persons, 266  
laboratory evaluation of, 856  
noncholera *Vibrio*, 1065-1066, 1065t  
noninflammatory, 852t  
pathogenesis of, 265-266, 852-853, 852t  
penetrating, 852t  
prevention of, 857  
protozoal, 1405-1409  
*Salmonella*. *See* *Salmonella* spp. infections  
*Shigella*. *See* *Shigella* spp. infections  
with systemic manifestations, 266-267  
*T. whipplei*, 1092  
treatment of, 856-857, 857t, 1031  
*V. cholera*. *See* Cholera  
in irritable bowel syndrome, 1965  
in malabsorption syndromes, 1932-1933, 1937, 1946t  
metabolic acidosis in, 298, 320  
osmotic, 303, 1933  
overflow, 265  
paraneoplastic, 609t  
persistent, 265  
postvagotomy, 1926  
in protein-losing enteropathy, 1945  
secretory, 303, 1933  
in short bowel syndrome, 1943  
traveler's. *See* Travelers' diarrhea  
in tropical sprue, 1942  
in ulcerative colitis, 1952, 1952t  
in VIPoma, 570  
water loss in, 95e-1  
in Whipple's disease, 1945  
in ZES, 568, 1927
- Diarrhetic shellfish poisoning, 2741-2742
- Diarylquinolines, 205e-7
- Diascopy, 342
- Diastolic blood pressure, 1616t
- Diastolic dysfunction, 265e-10, 265e-10f, 270e-7, 270e-8f
- Diastolic failure. *See* Heart failure (HF)
- Diastolic murmur. *See* Heart murmurs
- Diatrizoate meglumine, 727t
- Diazepam  
for alcohol withdrawal, 2727  
for anxiety disorders, 2711t  
for cocaine toxicity, 469e-2  
drug interactions of, 246e-3t, 1921  
for insomnia, 65  
for marine envenomations, 2739  
for nerve agent exposure, 262e-5t, 262e-6-7, 262e-6f  
overdose/poisoning with, 473e-10t, 2764t  
pharmacology of, 2711t  
for sedation after myocardial infarction, 1606  
for spasticity, 2660, 2672  
for stiff-person syndrome, 618  
therapeutic monitoring of, 2764t  
for vertigo, 151t
- Diazoxide, 380, 569, 2434
- Dibasic aminoaciduria (lysinuric protein intolerance), 332e-7t, 435e-1t, 435e-2
- Dibutyl phthalate, 1963
- DIC. *See* Disseminated intravascular coagulation (DIC)
- Dicarboxylic aminoaciduria, 435e-1t
- DICER gene mutations, 594
- Dichloralphenazone, 2592, 2592t
- Dichloroacetate (DCA), 102e-13
- Dichromat, 197
- Dichuchwa. *See* Endemic syphilis
- Dick test, 966
- Diclofenac  
advantages of, 1923  
adverse effects of, 389t, 727t  
for gout, 2234  
for osteoarthritis, 2232t  
for pain, 91
- Dicloxacillin  
adverse effects of, 284, 306  
for auricular cellulitis, 228  
for impetigo, 967  
indications for, 937  
for otitis externa, 228  
for staphylococcal skin/soft tissue infections, 345, 768t, 962t
- Didanosine (ddI)  
adverse effects of, 2023, 2030  
drug interactions of, 1278, 2030  
molecular structure of, 1276f  
resistance to, 1279f
- Dideoxynucleosides, 1267
- DIDMOAD (Wolfram's) syndrome, 2276, 2348
- Dientamoeba fragilis*, 246e-9, 765t, 1409
- Diet  
asthma and, 1670, 1671  
breast cancer and, 524  
for cancer prevention, 476  
cardiovascular disease and, 266e-4  
colorectal cancer and, 538  
composition of, 95e-4  
in elderly, 84-85  
energy density of, 2395  
global considerations in, 266e-4  
infectious disease exposure and, 763  
low-bacteria, 492  
lung cancer and, 506  
nephrolithiasis and, 1867, 1870  
peptic ulcer disease and, 1917
- Dietary assessment. *See* Nutritional assessment
- Dietary fiber  
cancer and, 476  
colorectal cancer and, 538  
for constipation, 273, 274  
for irritable bowel syndrome, 1969
- Dietary reference intakes, 95e-1
- Dietary supplements, 14e-3-4, 14e-4t, 95e-3
- Dietary Supplements Health and Education Act (DSHEA), 14e-3
- Diet history, 95e-5
- Diethylcarbamazine (DEC)  
action of, 246e-8  
adverse effects of, 246e-6t, 1419  
for loiasis, 1422  
for lymphatic filariasis, 1419  
pharmacology of, 246e-8  
for tropical pulmonary eosinophilia, 1420
- Diethylene glycol poisoning, 64e-9
- Diethylpropion, 2396
- Diethylstilbestrol (DES), 103e-15, 477t, 585
- Diet therapy. *See* Nutritional support/therapy
- Dieulafoy's lesion, 277, 346e-1v, 1891, 1891f
- Differentiation, in cancer cells, 103e-6
- Diffuse alveolar hemorrhage, 245
- Diffuse axonal injury, 457e-2, 457e-2f
- Diffuse esophageal spasm, 256, 1905-1906, 1906f
- Diffuse fasciitis with eosinophilia, 376
- Diffuse idiopathic skeletal hyperostosis (DISH), 2172
- Diffuse infiltrative lymphocytosis syndrome (DILS), 1260-1261
- Diffuse large B-cell lymphoma, **705**  
clinical features of, 702t, 705  
diagnosis of, 705, 705f  
genetic considerations in, 698-699, 699t, 705  
in HIV infection, 1270  
lymph node examination in, 81e-10f, 705f